Mercedes-Benz Group AG

German premium car maker Mercedes-Benz <a href="https://group.mercedes-benz.com/investors/reports-news/annual-reports/2025/">reported</a> a sharp drop in annual profit and warned of a challenging outlook amid global duties and increasing competition from Chinese manufacturers. The company's shares fell 2% after the report was published, but then recovered some of the losses.

Mercedes-Benz profits more than halved due to duties and China. What about the stock?

BETA Technologies, Inc.

Shares of mid-cap electric aircraft maker Beta Technologies <a href="https://finance.yahoo.com/quote/BETA/">jumped</a>&nbsp;almost 16% on Wednesday, February 11. The company <a href="https://investors.beta.team/financials/annual-reports/content/0001104659-26-012665/primary_doc.html">disclosed</a>&nbsp;that more than 5% of its shares are owned by technology giant Amazon. At the same time, investment bank Jefferies upgraded the stock to “buy,” which makes Wall Street unanimous in its bullish stance on Beta.

Mid-cap electric airplane maker Beta soars 16% as Jefferies upgrades to 'buy'

Artificial intelligence is already writing code instead of programmers. How do people who don't understand technology keep their jobs?

"The Most Important Year": a startup's viral essay on how to save careers in the age of AI

Energy Fuels Inc.

Goldman Sachs has&nbsp;<a href="https://www.cnbc.com/2026/02/11/biggest-stocks-wednesday-by-analyst-calls-like-nvidia.html">initiated coverage</a> of mid-cap uranium producer Energy Fuels with a "buy" rating. The company <a href="https://en.oninvest.com/article/beyond-intel-small-energy-defense-stocks-set-to-gain-from-trump-natsec-spending">owns</a>&nbsp;the only U.S. facility capable of processing both conventional uranium and rare earth elements, Goldman Sachs explained.

'Uniquely positioned': Goldman initiates on uranium company Energy Fuels with 'buy'

Nebius Group N.V.

Cloud provider Nebius Group's 2025 revenue <a href="https://assets.nebius.com/assets/04f48f4e-48e9-468e-a428-ef16565c3fb5/Financial%20results_Q4%202025_11022026.pdf?cache-buster=2026-02-12T11:56:40.932Z">grew</a> 479% year-over-year to $529.8 million versus $91.5 million a year earlier. At the same time, the company's annualized recurring revenue (ARR) exceeded $1 billion at the end of the year, according to a letter from founder and CEO Arkady Volozh to shareholders.

Volozh's AI company Nebius grew revenue nearly 6x year over year

SK hynix Inc.

Micron Technology, Inc.

Samsung Electronics Co., Ltd.

NVIDIA Corporation


This is an important milestone against other memory players SK Hynix and Micron

Samsung was the first among its competitors to start shipping new memory chips. Shares jumped

Hermes International Societe en commandite par actions

The loyalty of wealthy Hermes customers has allowed the fashion house to raise prices by 5-6% in early 2026

Hermes sales exceeded expectations thanks to strong demand for Birkin bags

Cisco Systems, Inc.

AppLovin Corporation

Equinix, Inc.

Rollins, Inc.

AST SpaceMobile, Inc.

Cognex Corporation

T-Mobile US, Inc.

Vertiv Holdings Co

Generac Holdings Inc.

Solstice Advanced Materials, Inc.

Moderna, Inc.

Daily review and forecast of events on the U.S. stock market from Mikhail Denislamov, Deputy Director of Freedom Capital Markets Research.

Morning in New York: investors in search of new benchmarks

ARKO Petroleum Corp. Class A Common Stock

Freedom clients can now participate in early trading in shares of fuel wholesaler ARKO Petroleum on the Freedom trading platform. It is the fuel wholesaler subsidiary of convenience store firm ARKO Corp. Later on Thursday, Friday 12, the company’s shares will debut during the Nasdaq regular session under the ticker <a href="https://tap.freedom24.com/to/quote/APC.US?utm_source=stocks&amp;utm_medium=APC.US&amp;utm_campaign=pfu15685513">APC</a>.

ARKO Petroleum IPO: Spun-off fuel wholesaler goes public on the Nasdaq

Relmada Therapeutics, Inc.

In 2025, shares of biotech Relmada Therapeutics surged more than 800%. The company executed a strategic pivot after its lead experimental therapy – a program developed for more than 15 years – <a href="https://www.relmada.com/for-investors/news/detail/306/relmada-therapeutics-reports-that-data-monitoring-committee">failed</a> in clinical trials in December 2024. The setback triggered a <a href="https://finance.yahoo.com/quote/RLMD/">sharp selloff</a> in the stock and raised questions about the company’s ability to continue operations. So why does Wall Street <a href="https://www.marketwatch.com/investing/stock/rlmd/analystestimates?mod=mw_quote_tab">now see</a> as much as 140% upside?

Why Wall Street still sees upside in biotech Relmada after 800% growth in 2025

The legendary investor explained in a new interview why fiat currencies are inevitably losing to gold, what the threat of the yuan is and how to protect your capital

How investors can protect themselves when things fall apart: tips from Ray Dalio

Apple Inc.

The company's stock outlook is directly tied to the introduction of AI features in the iPhone

Small caps